title: Efficacy of one-day quadruple therapy for H pylori infection in Chinese patients.
abstract: OBJECTIVE
  To compare the efficacies of one-day quadruple therapy and seven-day triple therapy in Chinese patients.
  
  
  METHODS
  Sixty consecutive patients with nonulcer dyspepsia and confirmed H pylori infection were randomized to receive either omeprazole 40 mg, amoxycillin 1 g, and furazolidone 100 mg, all twice a day for 7 d or omeprazole 20 mg (at breakfast and dinner), amoxicillin 1 g, furazolidone 200 mg, and colloidal bismuth subcitrate 220 mg four times for only one day. H pylori status was determined before and at least 5 weeks after therapy by endoscopy with antral and corpus biopsies for rapid urease test and histology.
  
  
  RESULTS
  H pylori eradication was successful in 66.67% (20/30) patients in the 7-d group and in 36.67% (11/30) patients in the 1-d group (P = 0.037). Side effects were induced by the treatment in 13.3% (4/30) patients of each group, but these were all self-limiting, short-lasting, and did not require any specific treatment.
  
  
  CONCLUSIONS
  The one-day quadruple therapy is less effective than the one-week regimen in curing H pylori infection in Chinese patients.
authors.affiliation: Department of Gastroenterology, First Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Huo
authors.forename: Jian-Kun
authors.initials: JK
authors.lastname: Chu
authors.forename: Xiu-Fen
authors.initials: XF
authors.lastname: Yang
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Li-Jing
authors.initials: LJ
authors.lastname: Zhang
authors.forename: Jin-Cheng
authors.initials: JC
authors.lastname: Ma
authors.forename: Jun
authors.initials: J
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D044466:Asian People; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005664:Furazolidone / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011706:Pyloric Antrum / Q000382:microbiology / Q000473:pathology; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D005664:Furazolidone; D000658:Amoxicillin; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole